A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
Study sponsor: Madrigal Pharmaceuticals, Inc. · MDGL
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-01-06Actual
Enrollment · participants1343Actual
Source updated2023-09-05Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.